AHK-Cu
Also known as: L-alanyl-L-histidyl-L-lysine-Cu2+, tripeptide-copper complex, AHK copper complex
Copper-binding tripeptide / growth factor peptide
What it is
AHK-Cu is a copper-binding peptide people use for hair growth and scalp health. Limited research suggests it may stimulate hair follicle activity in lab settings. No FDA-approved use; evidence comes from one published study and is at an early stage.
The scientific side
Based on the single available abstract, AHK-Cu (L-alanyl-L-histidyl-L-lysine-Cu2+) is described as a growth factor for various kinds of differentiated cells. In the context of hair biology, AHK-Cu stimulated the elongation of human hair follicles ex vivo and the proliferation of dermal papilla cells (DPCs) in vitro. At 10⁻⁹ M, AHK-Cu elevated the Bcl-2/Bax ratio and reduced levels of cleaved caspase-3 and PARP, suggesting an anti-apoptotic effect in DPCs. The compound is also reported to stimulate dermal fibroblast proliferation, elevate vascular endothelial growth factor (VEGF) production, and decrease transforming growth factor-beta1 (TGF-β1) secretion by dermal fibroblasts. The proposed mechanism for hair growth promotion is stimulation of DPC proliferation and preclusion of DPC apoptosis.
Class: Copper-binding tripeptide / growth factor peptide
Administration & storage
- Cautions
- No human pharmacokinetic or safety data are available in the reviewed literature.,All dose data derive from in vitro / ex vivo experiments; translation to human dosing has not been established in the reviewed literature.,No formulation, purity, or sterility specifications for injectable or topical use are described in the available abstract.,Sterile technique should always be applied when handling any peptide preparation intended for administration — general best practice.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Hair follicle growth promotion / androgenetic alopecia or hair loss In vitro only
- AHK-Cu (10⁻¹² – 10⁻⁹ M) stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells (DPCs) in vitro. At 10⁻⁹ M, the Bcl-2/Bax ratio was elevated and cleaved caspase-3 and PARP levels were reduced, suggesting reduced DPC apoptosis. The compound also stimulates dermal fibroblast prolif PMID 17703734 Pyo HK et al. Archives of Pharmacal Research (2007)
Safety signals
- Reduction in apoptotic DPCs at 10⁻⁹ M was observed but was not statistically significant (Annexin V-FITC/PI flow cytometry); no adverse safety signals reported in the reviewed abstract. PMID 17703734
Protocol
1-2 mg topical (dissolved in serum, lotion, or carrier solution), once or twice daily. Cycle: 4-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| In vitro / ex vivo (applied to cultured cells and isolated hair follicles) | 10⁻¹² – 10⁻⁹ M (in vitro / ex vivo concentration range) | Not explicitly stated for duration; single-experiment concentrations | in_vitro | Research PMID 17703734 |
| topical (dissolved in serum, lotion, or carrier solution) | 1-2 mg | once or twice daily · 4-12 weeks | biohackers and skincare enthusiasts seeking anti-aging, skin repair, or hair growth | [Community] |
| topical (scalp application) | 1 mg | once daily · 8-16 weeks | biohackers and individuals experiencing hair thinning or loss | [Community] |
| topical (scalp application) | 2 mg | once daily · 8-16 weeks | biohackers pursuing more aggressive hair regrowth protocols | [Community] |
| topical (wound or scar site) | 1-2 mg | once or twice daily · 4-8 weeks | biohackers and self-experimenting individuals targeting scar reduction or wound healing | [Community] |
| topical (facial) | 1 mg | once daily (evening) · 8-12 weeks | skincare-focused biohackers, typically adults 30+ seeking skin texture and tone improvement | [Community] |
All studies (1)
- PMID 17703734 In vitro only
Hair follicle growth promotion / androgenetic alopecia or hair loss
Frequently asked
What is AHK-Cu and what is it used for?
AHK-Cu (L-alanyl-L-histidyl-L-lysine-Cu2+) is a copper-binding tripeptide described in published research as a growth factor for differentiated cells. One peer-reviewed study found that AHK-Cu stimulated human hair follicle elongation ex vivo and promoted proliferation of dermal papilla cells in vitro, while also showing signs of reducing cell apoptosis. It has also been reported to stimulate dermal fibroblast proliferation, increase VEGF production, and decrease TGF-β1 secretion. Note: all available evidence is from in vitro and ex vivo experiments.
What dose of AHK-Cu should I take or inject?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the only published study I have data from used in vitro / ex vivo concentrations of 10⁻¹² – 10⁻⁹ M applied directly to cultured cells and isolated hair follicles. These are laboratory concentrations and cannot be directly translated to human dosing.
Has AHK-Cu been tested in humans?
Based on the single abstract available to me, AHK-Cu was studied using human-derived hair follicles and dermal papilla cells in an ex vivo / in vitro setting — not in a clinical trial with human participants receiving the compound. No human clinical trial data are present in the reviewed literature.
What is the mechanism by which AHK-Cu promotes hair growth?
According to PMID 17703734, the proposed mechanism is two-fold: (1) stimulation of dermal papilla cell (DPC) proliferation and (2) preclusion of DPC apoptosis. At 10⁻⁹ M, AHK-Cu elevated the Bcl-2/Bax ratio and reduced cleaved caspase-3 and PARP levels, which are markers associated with reduced apoptosis. The compound is also described as stimulating VEGF production and reducing TGF-β1 secretion by dermal fibroblasts.
Is AHK-Cu FDA-approved?
The reviewed literature does not address the FDA approval status of AHK-Cu. Please consult official FDA databases or a licensed healthcare provider for current regulatory information.
Can I stack AHK-Cu with other peptides like GHK-Cu or minoxidil?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: AHK-Cu has been evaluated alone in one in vitro/ex vivo hair growth study. No combination studies are present in the reviewed literature.
Where can I buy AHK-Cu?
I don't recommend vendors or sources. Please consult a licensed provider.
Are there any side effects or safety concerns with AHK-Cu?
The only available abstract does not report any adverse effects, but this was an in vitro / ex vivo study and was not designed to assess clinical safety. No human safety, tolerability, or pharmacokinetic data are present in the reviewed literature. Please consult a licensed healthcare provider before considering use.
Can AHK-Cu treat my hair loss condition?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. What the available research shows is limited to in vitro and ex vivo findings in human hair follicle and dermal papilla cell models; no clinical efficacy data in patients are available in the reviewed literature.
How should AHK-Cu be stored or reconstituted?
I don't have reliable study data on that specific question from the reviewed literature — the available abstract does not describe storage conditions or reconstitution procedures. I won't guess — please consult a licensed provider or peer-reviewed literature directly.